Alpha Tau Medical
DRTS
23 hedge funds and large institutions have $3.65M invested in Alpha Tau Medical in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 0 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
15% more funds holding
Funds holding: 20 → 23 (+3)
0.03% more ownership
Funds ownership: 1.37% → 1.4% (+0.03%)
11% less capital invested
Capital invested by funds: $4.11M → $3.65M (-$455K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
H
HoyleCohen
San Diego,
California
|
+$986K |
| 2 |
LCS
Levin Capital Strategies
New York
|
+$238K |
| 3 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
+$44K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.67K |
| 5 |
JP Morgan Chase
New York
|
+$1.74K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$1.18M |
DRTS Hedge Fund Activity: Q3 2023 in Review
23 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Alpha Tau Medical (DRTS) for Q3 2023, worth a combined $3.65M — down 11% from $4.11M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new DRTS positions and 0 closed out — a net gain of 3 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was HoyleCohen, opening a new position worth an estimated $986K. The largest seller was Citigroup, cutting an estimated $1.18M.
- 23 institutional investors held Alpha Tau Medical (DRTS) as of Q3 2023, up from 20 in Q2 2023.
- Funds reported $3.65M of Alpha Tau Medical stock for Q3 2023, down 11% quarter-over-quarter.
- 3 funds opened new Alpha Tau Medical positions in Q3 2023 and 0 closed out, a net change of +3 holders.
- The largest Alpha Tau Medical buyer in Q3 2023 was HoyleCohen, an estimated $986K added.
- The largest Alpha Tau Medical seller in Q3 2023 was Citigroup, an estimated $1.18M sold.
Based on aggregated 13F filings for Q3 2023.